{"id":816177,"date":"2026-05-28T17:30:03","date_gmt":"2026-05-28T17:30:03","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=816177"},"modified":"2026-05-28T17:30:03","modified_gmt":"2026-05-28T17:30:03","slug":"brain-cancer-market-to-witness-transformational-growth-opportunities-by-2036-delveinsight-roche-jazz-pharma-merck-daiichi-sankyo-novartis-bayer-laminar-pharma-aivita-biomedical-denovo","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/brain-cancer-market-to-witness-transformational-growth-opportunities-by-2036-delveinsight-roche-jazz-pharma-merck-daiichi-sankyo-novartis-bayer-laminar-pharma-aivita-biomedical-denovo_816177.html","title":{"rendered":"Brain Cancer Market to Witness Transformational Growth Opportunities by 2036 \u2013 DelveInsight | Roche, Jazz Pharma, Merck, Daiichi Sankyo, Novartis, Bayer, Laminar Pharma, Aivita Bio-medical, Denovo"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/upload\/2026\/05\/1779985253.jpg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Brain Cancer Market to Witness Transformational Growth Opportunities by 2036 &ndash; DelveInsight | Roche, Jazz Pharma, Merck, Daiichi Sankyo, Novartis, Bayer, Laminar Pharma, Aivita Bio-medical, Denovo\" src=\"https:\/\/www.abnewswire.com\/upload\/2026\/05\/1779985253.jpg\" alt=\"Brain Cancer Market to Witness Transformational Growth Opportunities by 2036 &ndash; DelveInsight | Roche, Jazz Pharma, Merck, Daiichi Sankyo, Novartis, Bayer, Laminar Pharma, Aivita Bio-medical, Denovo\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">The Key Brain Cancer Companies in the market include &#8211; Roche, Jazz Pharmaceuticals, Merck, Daiichi Sankyo, Novartis, Bayer, Laminar Pharmaceuticals, Aivita Bio-medical, Denovo Pharma, Kazia Therapeutics, Orbus Therapeutics, Eisai, Immunomic Therapeutics, Servier, Medicenna Therapeutics, NatureWise Biotech, medac GmbH, Crown Bioscience, DUSA Pharmaceuticals, Inc., Bayer, Ono Pharmaceutical Co. Ltd, Neurobiological Technologies,  Monte Verde SA, Pfizer, and others.<\/div>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s<strong> &ldquo;Brain Cancer Market Insights, Epidemiology, and Market Forecast-2036&Prime;<\/strong> report offers an in-depth understanding of the Brain Cancer, historical and forecasted epidemiology as well as the Brain Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get a Free sample for the Brain Cancer Market Forecast, Size &amp; Share Analysis Report: <\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/brain-cancer-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">https:\/\/www.delveinsight.com\/report-store\/brain-cancer-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key facts of the Brain Cancer Market Report: <\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>The Brain Cancer market size reached an estimated value of <strong>USD 2,800 million in 2025<\/strong> and is anticipated to expand at a <strong>CAGR of 2.5%<\/strong> throughout the forecast period from 2026 to 2036.<\/p>\n<\/li>\n<li>\n<p>According to DelveInsight estimates, the United States represented the largest share of the brain cancer market in 2025, with a market size of nearly <strong>USD 1,500 million<\/strong>. Recent assessments further indicate potential market expansion supported by the growing adoption of innovative and targeted treatment approaches.<\/p>\n<\/li>\n<li>\n<p><strong>In January 2026, Bayer<\/strong> reported ongoing evaluation of regorafenib in glioblastoma through platform trials such as GBM AGILE, highlighting its continued investigation in both newly diagnosed and recurrent settings.<\/p>\n<\/li>\n<li>\n<p><strong>In November 2025, Northwest Biotherapeutics<\/strong> advanced regulatory engagement for DCVax-L following Phase III data demonstrating improved overall survival in glioblastoma patients, with efforts focused on potential approvals.<\/p>\n<\/li>\n<li>\n<p><strong>In September 2025, Daiichi Sankyo<\/strong> continued post-marketing and clinical development activities for teserpaturev (DELYTACT), an oncolytic virus approved in Japan for malignant glioma, with additional studies exploring global expansion opportunities.<\/p>\n<\/li>\n<li>\n<p><strong>In August 2025, Jazz Pharma<\/strong> announced US FDA approval of MODEYSO as the first and only treatment for recurrent H3 K27 M-mutant diffuse midline glioma.<\/p>\n<\/li>\n<li>\n<p>According to the estimates, the United States recorded the highest market share, i.e., around 65% of the total market size of brain cancer, in 2025.<\/p>\n<\/li>\n<li>\n<p>Among the EU4 and the UK, Germany has the maximum revenue share in 2025, while Spain has the lowest market share.<\/p>\n<\/li>\n<li>\n<p>Conditional and time-limited approval of <strong>Daiichi&rsquo;s DELYTACT,<\/strong> an intratumoral oncolytic virus therapy, has opened new doors for other players, such as DNAtrix and Istari Oncology, to develop oncolytic virus therapies, which can prove to be a potential mechanism of action in brain cancer treatment in the future.<\/p>\n<\/li>\n<li>\n<p>According to DelveInsight&rsquo;s estimates, the total incident cases of brain cancer in the 7MM were approximately 62,800 in 2025.<\/p>\n<\/li>\n<li>\n<p>It has been observed that the incidence of high-grade brain tumors is higher (~70%) than that of low-grade brain tumors (~30%) in the United States.<\/p>\n<\/li>\n<li>\n<p>It is observed that brain tumors are found to be more common in males (~58%) as compared to females (~42%) in the United States.<\/p>\n<\/li>\n<li>\n<p>Among EU4 and the UK, Germany accounted for the highest number of glioma cases, followed by France, whereas Spain had the lowest number of cases in 2025.<\/p>\n<\/li>\n<li>\n<p>In 2025, among brain tumors in other parts of the central nervous system in the United States, glioblastoma was more common in adults than in pediatrics, followed by anaplastic astrocytoma, which was also found to be more prevalent in adults than in pediatrics.<\/p>\n<\/li>\n<li>\n<p>In the United States, among all the age groups, 40&ndash;64 years accounted for the highest number of brain tumor cases, i.e., around 44%, in 2025, followed by the age group &ge;65 years (39%).<\/p>\n<\/li>\n<li>\n<p><strong>Key Brain Cancer Companies:<\/strong> Roche, Jazz Pharmaceuticals, Merck, Daiichi Sankyo, Novartis, Bayer, Laminar Pharmaceuticals, Aivita Bio-medical, Denovo Pharma, Kazia Therapeutics, Orbus Therapeutics, Eisai, Immunomic Therapeutics, Servier, Medicenna Therapeutics, NatureWise Biotech, medac GmbH, Crown Bioscience, DUSA Pharmaceuticals, Inc., Bayer, Ono Pharmaceutical Co. Ltd, NewLink Genetics Corporation, TransMolecular, Genzyme, Eli Lilly and Company, Direct Therapeutics, InSightec, Neurobiological Technologies, Monte Verde SA, Pfizer, and others<\/p>\n<\/li>\n<li>\n<p><strong>Key Brain Cancer Therapies:<\/strong> Bevacizumab (AVASTIN), Dordaviprone (MODEYSO), Temozolomide (TEMODAR), Delytact, TAFINLAR (dabrafenib) + MEKINIST (trametinib), Regorafenib, LAM561 (2-OHOA), AV-GBM-1, Enzastaurin, Paxalisib (GDC-0084), Eflornithine + Lomustine, LENVIMA + KEYTRUDA, ITI-1000, Vorasidenib (AG-881), MDNA55, NBM-BMX Capsule, Gliolan, Karenitecin (BNP1350), Tumor fluorescence, Magnevist (SH L 451A), Nivolumab, Indoximod, 131I-TM-601, 89Zr-GC1008, abemaciclib, DTI-015, Doxorubicin, hCRF, Temozolomide, Palbociclib, and others<\/p>\n<\/li>\n<li>\n<p>The Brain Cancer epidemiology based on gender analyzed that Brain Tumors is slightly more common in men as compared to women<\/p>\n<\/li>\n<li>\n<p>The Brain Cancer market is expected to surge due to the disease&#8217;s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Brain Cancer pipeline products will significantly revolutionize the Brain Cancer market dynamics.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Brain Cancer Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Brain cancer refers to the abnormal and uncontrolled growth of cells in the brain, leading to the formation of a tumor. There are various types of brain tumors, and they can be either benign (non-cancerous) or malignant (cancerous). Malignant tumors, also known as brain cancer, have the potential to invade nearby tissues and spread to other parts of the brain or the central nervous system.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To Know in detail about the Brain Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/brain-cancer-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Brain Cancer Market Forecast<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Brain Cancer Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify;\">The Brain Cancer epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Brain Cancer Epidemiology Segmentation:<\/strong><\/p>\n<p style=\"text-align: justify;\">The Brain Cancer market report proffers epidemiological analysis for the study period 2022&ndash;2036 in the 7MM segmented into:<\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Total Incident Cases of Brain Tumor\/Central Nervous System<\/p>\n<\/li>\n<li>\n<p>Total Incident Cases of Brain Cancer<\/p>\n<\/li>\n<li>\n<p>Grade-Specific Incident Cases of Brain Cancer<\/p>\n<\/li>\n<li>\n<p>Type-Specific Incident Cases of Brain Cancer<\/p>\n<\/li>\n<li>\n<p>Gender-Specific Incident Cases of Brain Cancer<\/p>\n<\/li>\n<li>\n<p>Age-Specific Incident Cases of Brain Cancer<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download the report to understand which factors are driving Brain Cancer epidemiology trends @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/brain-cancer-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Brain Cancer Epidemiology Forecast<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Brain Cancer Drugs Uptake and Pipeline Development Activities<\/strong><\/p>\n<p style=\"text-align: justify;\">The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Brain Cancer market or expected to get launched during the study period. The analysis covers Brain Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.<\/p>\n<p style=\"text-align: justify;\">Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.<\/p>\n<p style=\"text-align: justify;\">The report also covers the Brain Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Brain Cancer Therapies and Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p><strong>Bevacizumab (AVASTIN):<\/strong> Roche<\/p>\n<\/li>\n<li>\n<p><strong>Dordaviprone (MODEYSO):<\/strong> Jazz Pharmaceuticals<\/p>\n<\/li>\n<li>\n<p><strong>Temozolomide (TEMODAR):<\/strong> Merck<\/p>\n<\/li>\n<li>\n<p><strong>Delytact:<\/strong> Daiichi Sankyo<\/p>\n<\/li>\n<li>\n<p><strong>TAFINLAR (dabrafenib) + MEKINIST (trametinib):<\/strong> Novartis<\/p>\n<\/li>\n<li>\n<p><strong>Regorafenib:<\/strong> Bayer<\/p>\n<\/li>\n<li>\n<p><strong>LAM561 (2-OHOA):<\/strong> Laminar Pharmaceuticals<\/p>\n<\/li>\n<li>\n<p><strong>AV-GBM-1:<\/strong> Aivita Bio-medical<\/p>\n<\/li>\n<li>\n<p><strong>Enzastaurin:<\/strong> Denovo Pharma<\/p>\n<\/li>\n<li>\n<p><strong>Paxalisib (GDC-0084):<\/strong> Kazia Therapeutics<\/p>\n<\/li>\n<li>\n<p><strong>Eflornithine + Lomustine:<\/strong> Orbus Therapeutics<\/p>\n<\/li>\n<li>\n<p><strong>LENVIMA + KEYTRUDA:<\/strong> Eisai<\/p>\n<\/li>\n<li>\n<p><strong>ITI-1000:<\/strong> Immunomic Therapeutics<\/p>\n<\/li>\n<li>\n<p><strong>Vorasidenib (AG-881):<\/strong> Servier<\/p>\n<\/li>\n<li>\n<p><strong>MDNA55:<\/strong> Medicenna Therapeutics<\/p>\n<\/li>\n<li>\n<p><strong>NBM-BMX Capsule:<\/strong> NatureWise Biotech<\/p>\n<\/li>\n<li>\n<p><strong>Gliolan:<\/strong> medac GmbH<\/p>\n<\/li>\n<li>\n<p><strong>Karenitecin (BNP1350):<\/strong> Crown Bioscience<\/p>\n<\/li>\n<li>\n<p><strong>Tumor fluorescence:<\/strong> DUSA Pharmaceuticals, Inc.<\/p>\n<\/li>\n<li>\n<p><strong>Magnevist (SH L 451A):<\/strong> Bayer<\/p>\n<\/li>\n<li>\n<p><strong>Nivolumab:<\/strong> Ono Pharmaceutical Co. Ltd<\/p>\n<\/li>\n<li>\n<p><strong>Indoximod:<\/strong> NewLink Genetics Corporation<\/p>\n<\/li>\n<li>\n<p><strong>131I-TM-601:<\/strong> TransMolecular<\/p>\n<\/li>\n<li>\n<p><strong>89Zr-GC1008:<\/strong> Genzyme<\/p>\n<\/li>\n<li>\n<p><strong>abemaciclib:<\/strong> Eli Lilly and Company<\/p>\n<\/li>\n<li>\n<p><strong>DTI-015:<\/strong> Direct Therapeutics<\/p>\n<\/li>\n<li>\n<p><strong>Doxorubicin:<\/strong> InSightec<\/p>\n<\/li>\n<li>\n<p><strong>hCRF:<\/strong> Neurobiological Technologies<\/p>\n<\/li>\n<li>\n<p><strong>Temozolomide:<\/strong> Monte Verde SA<\/p>\n<\/li>\n<li>\n<p><strong>Palbociclib:<\/strong> Pfizer<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Discover more about therapies set to grab major Brain Cancer market share @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/brain-cancer-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Brain Cancer Treatment Landscape<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Brain Cancer Market Strengths<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Rise in brain cancer market is attributed to several factors such as aging population, evolving research, more diagnostic tests, developing surgical approaches, improved radiotherapy techniques and novel systemic therapies.<\/p>\n<\/li>\n<li>\n<p>Various intratumoral therapies are under development which will help in overcoming the challenge of delivering the drugs across the blood-brain barrier and provide better treatment outcomes.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Brain Cancer Market Opportunities<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Due to lack of competitors in anaplastic astrocytoma, there is a substantial market opportunity for key players to develop anaplastic tumor targeting therapies.<\/p>\n<\/li>\n<li>\n<p>Numerous failed clinical trials suggest combination therapies will likely be the most promising method of GBM treatment, and emphasis should be applied to drug design and pharmacokinetic properties<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Brain Cancer Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p><strong>Study Period: 2022&ndash;2036<\/strong><\/p>\n<\/li>\n<li>\n<p><strong>Coverage:<\/strong> 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]<\/p>\n<\/li>\n<li>\n<p><strong>Key Brain Cancer Companies:<\/strong> Roche, Jazz Pharmaceuticals, Merck, Daiichi Sankyo, Novartis, Bayer, Laminar Pharmaceuticals, Aivita Bio-medical, Denovo Pharma, Kazia Therapeutics, Orbus Therapeutics, Eisai, Immunomic Therapeutics, Servier, Medicenna Therapeutics, NatureWise Biotech, medac GmbH, Crown Bioscience, DUSA Pharmaceuticals, Inc., Bayer, Ono Pharmaceutical Co. Ltd, NewLink Genetics Corporation, TransMolecular, Genzyme, Eli Lilly and Company, Direct Therapeutics, InSightec, Neurobiological Technologies, Monte Verde SA, Pfizer, and others<\/p>\n<\/li>\n<li>\n<p><strong>Key Brain Cancer Therapies:<\/strong> Bevacizumab (AVASTIN), Dordaviprone (MODEYSO), Temozolomide (TEMODAR), Delytact, TAFINLAR (dabrafenib) + MEKINIST (trametinib), Regorafenib, LAM561 (2-OHOA), AV-GBM-1, Enzastaurin, Paxalisib (GDC-0084), Eflornithine + Lomustine, LENVIMA + KEYTRUDA, ITI-1000, Vorasidenib (AG-881), MDNA55, NBM-BMX Capsule, Gliolan, Karenitecin (BNP1350), Tumor fluorescence, Magnevist (SH L 451A), Nivolumab, Indoximod, 131I-TM-601, 89Zr-GC1008, abemaciclib, DTI-015, Doxorubicin, hCRF, Temozolomide, Palbociclib, and others<\/p>\n<\/li>\n<li>\n<p><strong>Brain Cancer Therapeutic Assessment:<\/strong> Brain Cancer current marketed and Brain Cancer emerging therapies<\/p>\n<\/li>\n<li>\n<p><strong>Brain Cancer Market Dynamics:<\/strong> Brain Cancer market drivers and Brain Cancer market barriers<\/p>\n<\/li>\n<li>\n<p><strong>Competitive Intelligence Analysis:<\/strong> SWOT analysis, PESTLE analysis, Porter&rsquo;s five forces, BCG Matrix, Market entry strategies<\/p>\n<\/li>\n<li>\n<p><strong>Brain Cancer Unmet Needs, KOL&rsquo;s views, Analyst&rsquo;s views, Brain Cancer Market Access and Reimbursement <\/strong><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To know more about Brain Cancer companies working in the treatment market, visit @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/brain-cancer-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Brain Cancer Clinical Trials and Therapeutic Assessment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents <\/strong><\/p>\n<p style=\"text-align: justify;\">1. Brain Cancer Market Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary for Brain Cancer<\/p>\n<p style=\"text-align: justify;\">3. SWOT analysis of Brain Cancer<\/p>\n<p style=\"text-align: justify;\">4. Brain Cancer Patient Share (%) Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. Brain Cancer Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">6. Brain Cancer Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">7. Brain Cancer Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Country-Specific Patient Population of Brain Cancer<\/p>\n<p style=\"text-align: justify;\">9. Brain Cancer Current Treatment and Medical Practices<\/p>\n<p style=\"text-align: justify;\">10. Brain Cancer Unmet Needs<\/p>\n<p style=\"text-align: justify;\">11. Brain Cancer Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">12. Brain Cancer Market Outlook<\/p>\n<p style=\"text-align: justify;\">13. Country-Wise Brain Cancer Market Analysis (2022&ndash;2036)<\/p>\n<p style=\"text-align: justify;\">14. Brain Cancer Market Access and Reimbursement of Therapies<\/p>\n<p style=\"text-align: justify;\">15. Brain Cancer Market Drivers<\/p>\n<p style=\"text-align: justify;\">16. Brain Cancer Market Barriers<\/p>\n<p style=\"text-align: justify;\">17. Brain Cancer Appendix<\/p>\n<p style=\"text-align: justify;\">18. Brain Cancer Report Methodology<\/p>\n<p style=\"text-align: justify;\">19. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">20. Disclaimer<\/p>\n<p style=\"text-align: justify;\">21. About DelveInsight<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight <\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p style=\"text-align: justify;\">It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_72253.html\" rel=\"nofollow\">DelveInsight<\/a><br \/><strong>Contact Person:<\/strong> Gaurav Bora<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=brain-cancer-market-to-witness-transformational-growth-opportunities-by-2036-delveinsight-roche-jazz-pharma-merck-daiichi-sankyo-novartis-bayer-laminar-pharma-aivita-biomedical-denovo\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +14699457679 <br \/><strong>Address:<\/strong>304  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=brain-cancer-market-to-witness-transformational-growth-opportunities-by-2036-delveinsight-roche-jazz-pharma-merck-daiichi-sankyo-novartis-bayer-laminar-pharma-aivita-biomedical-denovo\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Key Brain Cancer Companies in the market include &#8211; Roche, Jazz Pharmaceuticals, Merck, Daiichi Sankyo, Novartis, Bayer, Laminar Pharmaceuticals, Aivita Bio-medical, Denovo Pharma, Kazia Therapeutics, Orbus Therapeutics, Eisai, Immunomic Therapeutics, Servier, Medicenna Therapeutics, NatureWise Biotech, medac GmbH, Crown Bioscience, &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/brain-cancer-market-to-witness-transformational-growth-opportunities-by-2036-delveinsight-roche-jazz-pharma-merck-daiichi-sankyo-novartis-bayer-laminar-pharma-aivita-biomedical-denovo_816177.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-816177","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/816177","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=816177"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/816177\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=816177"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=816177"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=816177"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}